Sheela Swamy, MD
Internal Medicine · Downers Grove, ILNPI 1831145416
Payments from drug & device makers
Across 391 payments — averaging $18.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$886
- Lilly USA, LLC$854
- Novo Nordisk$807
- GSK$489
- Boehringer Ingelheim$432
- plus $3K from 28 others
What the payments were for
- Food & beverage$6,95999%
- Education$961%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 57 | $1,075 |
| AbbVie(2 entities) | 47 | $886 |
| Lilly USA, LLC | 48 | $854 |
| Novo Nordisk | 48 | $807 |
| GSK | 30 | $489 |
| Boehringer Ingelheim | 22 | $432 |
| Pfizer | 27 | $377 |
| Xeris Pharmaceuticals, Inc. | 15 | $298 |
| Amgen | 16 | $268 |
| Novartis | 8 | $212 |
| E.r. Squibb & Sons, L.L.C. | 11 | $177 |
| Bayer | 9 | $168 |
| Johnson & Johnson | 7 | $147 |
| Merck | 6 | $89 |
| Sumitomo Pharma America, Inc. | 5 | $78 |
| Phathom Pharmaceuticals, Inc. | 5 | $77 |
| Abbott | 1 | $77 |
| Astellas Pharma US Inc | 4 | $75 |
| Exact Sciences | 4 | $68 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $52 |
| Teva Pharmaceuticals USA, Inc. | 2 | $47 |
| Ironwood Pharmaceuticals, Inc | 2 | $33 |
| Apellis Pharmaceuticals, Inc. | 1 | $30 |
| Otsuka America Pharmaceutical, Inc. | 2 | $29 |
| Supernus Pharmaceuticals, Inc. | 2 | $29 |
| Ipsen Biopharmaceuticals, Inc | 1 | $24 |
| Seqirus USA Inc | 1 | $24 |
| Edwards Lifesciences | 1 | $22 |
| Assertio Therapeutics, Inc. | 1 | $20 |
| Upsher-smith Laboratories LLC | 1 | $19 |
| Currax Pharmaceuticals LLC | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $19 |
| Inspire Medical Systems, Inc. | 1 | $17 |
| AMAG Pharmaceuticals, Inc. | 1 | $16 |
How this compares
$7,055 in reported general payments places this provider in the 90th percentile of 5,182 internal medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 70 | $103,180 |
| EliquisApixaban | 80 | $76,782 |
| OzempicSemaglutide | 50 | $59,348 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 67 | $54,074 |
| TrulicityDulaglutide | 39 | $47,089 |
| FarxigaDapagliflozin Propanediol | 49 | $46,964 |
| RybelsusSemaglutide | 18 | $38,780 |
| MounjaroTirzepatide | 32 | $31,656 |
| LinzessLinaclotide | 15 | $15,548 |
| JanuviaSitagliptin Phosphate | 19 | $13,066 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 18 | $11,643 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 50 | $11,067 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 55 | $10,430 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 28 | $8,768 |
| TradjentaLinagliptin | 13 | $8,686 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $432 | $111,86683 claims |
| Novo NordiskOzempic, Rybelsus | $807 | $98,12868 claims |
| PfizerEliquis, Prempro, Premarin | $377 | $82,449105 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $854 | $78,74571 claims |
| GSKTrelegy Ellipta, Shingrix, Arexvy | $489 | $73,908145 claims |
| AstraZenecaFarxiga, Symbicort | $1,075 | $49,96362 claims |
| AbbVieLinzess, Synthroid | $886 | $17,01734 claims |
| MerckJanuvia | $89 | $13,06619 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,182 internal medicine providers in Illinois.
Other internal medicine in Downers Grove
- Dennis LevinsonChicago$25.3M
- Mary BrownRockford$16M
- Andrew BartlettChampaign$4.1M
- Danny SugimotoChicago$4M
- Peter O DonnellChicago$3.9M
- Daniel CatenacciChicago$3.5M
- Jeffrey GeohasEvanston$2.3M
- Patricia WalshChicago$2.1M
- Merle DiamondChicago$1.7M
- Yoko MomoyamaLombard$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.